Abstract 2601
Background
Immune checkpoint inhibitors (ICIs) acting against CTLA-4 and PD-1 represent a strenght therapy in patients (pts) with metastatic melanoma (MM). Antineoplastic activity of ICIs through the activation of immune cells in tumor lesions raised challenge in evaluation of treatment response by imaging. Aim of this study was to compare diagnostic accuracy of different 18F-FDG PET/CT parameters (Metabolic Tumor Volume, MTV; Total Lesion Glycolisis, TLG; Maximum Standardised Uptake Value, SUVmax) to predict therapy response and clinical outcome in pts with MM treated with Ipilimumab (Ipi) and Nivolumab (Nivo) or Pembrolizumab (Pem) and to check for accuracy differences specific for the class of treatment.
Methods
57 MM pts receiving Ipi (25) or PD-1 inhibitors (Nivo 19; Pem 13) who performed a 18F-FDG PET/CT scan at the beginning (PET0) and after completion of Ipi or during anti PD-1 (PET1), were retrospectively evaluated. Response at PET1 was classified as PD, SD, PR and CR according to RECIST 1.1, EORTC criteria and by percentage change of MTV and TLG (cut off values: +43% for PD and -43% for PR, calculated by ROC analysis) of up to 5 target lesions. PET Response Evaluation Criteria for Immunotherapy (PERCIMT) were assessed alone and with the previously described parameters. Performance of each criteria at PET1 to predict pts having clinical benefit (CR, PR and SD) and no clinical benefit (PD) at 6 months since starting ICIs were assessed and correlated to time-to-progression.
Results
For Ipi pts group, best predictors of response were: variation of MTV (Sensitivity 1; Specificity 0.84; accuracy 0.96) and TLG (Se 0.89; Sp; 93.8; acc 0.92), with PERCIMT criteria for progressive disease. In anti-PD1 group overlapping predictivity values were found for EORTC, MTV and TLG (Se 0.95; Sp 1; Acc 0.97). Reliability of above parameters was also confirmed in predicting pts progression free survival at 12 and 24 months.
Conclusions
18F-FDG PET/CT performed 3 months later the first administration could predict response to ICIs and long-term patient clinical outcome. Performance of 18F-FDG PET/CT parameters and criteria in predicting response to ICIs is influenced by the class of treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Local Ethic committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2963 - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib
Presenter: Ira Pekker
Session: Poster Display session 3
Resources:
Abstract
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract